ReviewInternational journal of environmental research and public health2021
Drug-Drug Interactions in Vestibular Diseases, Clinical Problems, and Medico-Legal Implications.
Review in International journal of environmental research and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 22 citations in OpenAlex.
- A Cross-Sectional Survey of Cannabis Use and Utility Among Patients Experiencing Dizziness.Brain sciences · 2026Article
- Vestibular compensation: extended review.Frontiers in neurology · 2026Review
- Therapeutic Management of Vestibular Disorders During Pregnancy: A Narrative and Evidence-Based Review.Cureus · 2025Review
- Meclizine Use and Subsequent Falls Among Patients With Dizziness.JAMA otolaryngology-- head & neck surgery · 2025Article
- Enhancing patient care in BPPV-related residual dizziness: introducing the CLEAR algorithm to support BPPV-RD recognition and follow-up strategies.Frontiers in neurology · 2025Review
- Residual dizziness after BPPV management: exploring pathophysiology and treatment beyond canalith repositioning maneuvers.Frontiers in neurology · 2024Review
- The Risk of Drug Interactions in Older Primary Care Patients after Hospital Discharge: The Role of Drug Reconciliation.Geriatrics (Basel, Switzerland) · 2023Article
- The Pharmacological Treatment of Chronic Pain: From Guidelines to Daily Clinical Practice.Pharmaceutics · 2023Review
- Metalloproteases in Pain Generation and Persistence: A Possible Target?Biomolecules · 2023Review
- Effect of Statins on Lung Cancer Molecular Pathways: A Possible Therapeutic Role.Pharmaceuticals (Basel, Switzerland) · 2022Review
- The pharmacological treatment of acute vestibular syndrome.Frontiers in neurology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral vestibular disease can be treated with several approaches (e.g., maneuvers, surgery, or medical approach). Comorbidity is common in elderly patients, so polytherapy is used, but it can generate the development of drug-drug interactions (DDIs) that play a role in both adverse drug reactions and reduced adherence. For this reason, they need a complex kind of approach, considering all their individual characteristics. Physicians must be able to prescribe and deprescribe drugs based on a solid knowledge of pharmacokinetics, pharmacodynamics, and clinical indications. Moreover, full information is required to reach a real therapeutic alliance, to improve the safety of care and reduce possible malpractice claims related to drug-drug interactions. In this review, using PubMed, Embase, and Cochrane library, we searched articles published until 30 August 2021, and described both pharmacokinetic and pharmacodynamic DDIs in patients with vestibular disorders, focusing the interest on their clinical implications and on risk management strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.